Project Details
Description
A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS)
| Status | Finished |
|---|---|
| Effective start/end date | 7/7/08 → 6/30/13 |
Funding
- HOFFMANN-LA ROCHE PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.